ArticleBMC pregnancy and childbirth2025
Analysis of immune-related biomarkers in amniotic fluid embolism by sequencing data and bioinformatics.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAmniotic fluid embolism (AFE) represents an uncommon yet life-threatening obstetric emergency characterized by its sudden onset and significant contribution to maternal death. Immune dysregulation has been implicated as a key pathological mechanism in AFE progression. This investigation employed through comprehensive bioinformatics approaches transcriptomic profiling of clinical specimens to systematically identify immune-associated genetic alterations that can distinguish AFE - induced pulmonary embolism from normal controls.
methodsWe conducted RNA sequencing on clinical specimens to delineate differentially expressed genes associated with AFE pathogenesis and immune responses. Functional annotation and protein-protein interaction (PPI) networks were generated using specialized R packages. Machine learning algorithms facilitated the selection of candidate biomarkers, whose expression patterns were quantitatively assessed. Diagnostic performance was evaluated through nomogram construction, while immune cell infiltration patterns were characterized using computational deconvolution methods. Potential N6-methyladenosine (m6A) sites were predicted via established databases, and regulatory networks were reconstructed. Future validation will include quantitative Polymerase Chain Reaction (PCR) verification of critical gene expression.
resultsOur analysis identified two upregulated biomarkers (MMP9 and PPBP) in AFE samples. The constructed nomogram demonstrated that elevated biomarker scores correlated with increased AFE probability. Validation through calibration curves, decision curve analysis, and receiver operating characteristic curves confirmed robust predictive accuracy and clinical applicability. Immunological assessment revealed significant negative correlations between biomarker expression and central memory CD4 + T cells, activated CD8 + T cells, and activated dendritic cells. Both biomarkers exhibited moderate to high-confidence RNA methylation sites.
conclusionWe have provided valuable peripheral blood sequencing data from AFE patients and healthy controls. Through bioinformatics analysis, we identified two immune-related biomarkers: MMP9 and PPBP and systematically examines their biological significance through immune infiltration profiling, gene set enrichment, regulatory network construction, and pharmacological association studies. This study provides preliminary evidence for the diagnostic potential of these two markers for AFE and offers new insights for research into the immune response associated with AFE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.